An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED-Reference-Cited by-同舟云学术

An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED

Published:2017-01-30 Issue:4 Volume:13 Page:381-388
ISSN:1552-4450
Container-title:Nature Chemical Biology
language:en
Short-container-title:Nat Chem Biol

Author:

Qi Wei,Zhao Kehao,Gu Justin,Huang Ying,Wang Youzhen,Zhang Hailong,Zhang Man,Zhang Jeff,Yu Zhengtian,Li Ling,Teng Lin,Chuai Shannon,Zhang Chao,Zhao Mengxi,Chan HoMan,Chen Zijun,Fang Douglas,Fei Qi,Feng Leying,Feng Lijian,Gao Yuan,Ge Hui,Ge Xinjian,Li Guobin,Lingel Andreas,Lin Ying,Liu Yueqin,Luo Fangjun,Shi Minlong,Wang Long,Wang Zhaofu,Yu Yanyan,Zeng Jue,Zeng Chenhui,Zhang Lijun,Zhang Qiong,Zhou Shaolian,Oyang Counde,Atadja Peter,Li En

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology

Link

http://www.nature.com/articles/nchembio.2304.pdf

Reference53 articles.

1. Kouzarides, T. Chromatin modifications and their function. Cell 128, 693–705 (2007).

2. Shilatifard, A. Chromatin modifications by methylation and ubiquitination: implications in the regulation of gene expression. Annu. Rev. Biochem. 75, 243–269 (2006).

3. Ernst, T. et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat. Genet. 42, 722–726 (2010).

4. Nikoloski, G. et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat. Genet. 42, 665–667 (2010).

5. De Raedt, T. et al. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature 514, 247–251 (2014).

Cited by 265 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PPARγ and C/EBPα enable adipocyte differentiation upon inhibition of histone methyltransferase PRC2 in malignant tumors;Journal of Biological Chemistry;2024-09

2. A CRISPR/Cas9 screen in embryonic stem cells reveals that Mdm2 regulates totipotency exit;Communications Biology;2024-07-03

3. Histone H3 Variants in the Multiverse of Cancer;Annual Review of Cancer Biology;2024-06-12

4. Therapeutic Discovery for Chromatin Complexes: Where Do We Stand?;Annual Review of Cancer Biology;2024-06-12

5. Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy;Cancer Discovery;2024-06-03